Phase 2/3 study evaluating safety, immunogenicity, and noninferiority of single booster dose of AVX/COVID-12 vaccine.

Sci Adv · 2025 · PMC12204155 · PMID 40577471

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

a notable trendno p-value reported

Although the study was not explicitly designed to evaluate vaccine efficacy, we observed a notable trend indicating that individuals boosted with AVX experienced fewer ambulatory COVID-19 cases than those in the AZ group.

also in 2,380 other papers

did not reach statistical significanceno p-value reported

In participants vaccinated with AVX, we observed a slight increase in total T cells and CD4 + T cells producing IFN-γ on day 14; however, this rise did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.